KalVista Reports Positive Phase 3 Pediatric Data for HAE Treatment EKTERLY

KalVista Pharmaceuticals (Nasdaq: KALV) has announced positive interim Phase 3 results from its KONFIDENT-KID trial evaluating EKTERLY (sebetralstat). The study focuses on children aged 2 to 11 years suffering from hereditary angioedema (HAE), a rare genetic condition. Notably, the KONFIDENT-KID trial represents the largest pediatric clinical study ever conducted within the HAE therapeutic area. The company aims to expand the indication of its lead candidate to younger populations using a proprietary oral disintegrating tablet formulation. This milestone significantly de-risks the regulatory path toward approval and broadens the drug's potential market reach. Investors view these results as a critical step in strengthening KalVista's position in the rare disease pharmaceutical sector.